Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation. MAPK pathway, involves three main kinases, Raf, MEK and ERK, has emerged as a novel target for the development of new cancer therapies with reduced side-effects.
MAPK inhibitors are being developed as small molecules, for the treatment of various types of cancer. They have also showed additional benefits with high effectiveness at lower concentrations in comparison to the ATP-competitive inhibitors, for the cancer therapy.
Mereo BioPharma Group plc is in the process of developing Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other companies having pipeline of MAPK inhibitors.
For more info about Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Get the sample report at: https://www.pharmaproff.com/request-sample/1206